# Platine, Avastin and OLAparib in 1st Line

> **NCT02477644** · PHASE3 · COMPLETED · sponsor: **Arcagy Research** · enrollment: 806 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02477644
- **Lead sponsor:** Arcagy Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-06
- **Primary completion:** 2019-03-22
- **Final completion:** 2022-03-22
- **Target enrollment:** 806 (ACTUAL)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477644, "Platine, Avastin and OLAparib in 1st Line". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02477644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*